Parasitic Protozoan (e.g., Trypanosoma, Trichomonas, Leishmania, Entamoeba, Etc.) Patents (Class 424/269.1)
  • Patent number: 10677798
    Abstract: Methods and compositions for detecting and diagnosing sexually transmitted infections using a string of epitopes (SOE) specific for detection of causative microorganisms are provided. The antigenic epitopes may be single epitope sequences, a plurality of epitope sequences joined by amino acid linkers to form a series of epitopes (SOE), or nucleotide sequences encoding one or more SOEs and host cells harboring said SOE nucleotide sequences. SOEs specific for highly immunogenic regions of proteins from Trichomonas, Treponema and Neisseria species are provided. SOEs to detect the presence of Trichomonas species comprise regions from Trichomonas aldolase, GAPDH, ?-enolase and ?-actinin proteins. Pharmaceutical compositions comprising SOEs can also be used as vaccines or to elicit an immune response to specific microorganisms.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: June 9, 2020
    Assignee: Washington State University
    Inventor: John F. Alderete
  • Patent number: 10213500
    Abstract: A monocomponent vaccine effective to moderate the clinical consequences of Chages disease, capable of stimulating an immune response against the trans-sialidase virulence factor of the Trypanosoma cruzi parasite. The vaccine active ingredient is an immunogenic component with a polynucleotide encoding one or more polypeptide(s) which includes a C-terminal region composed of at least two repetitive units of amino acids, with a polypeptide with trans-sialidase activity of Trypanosoma cruzi fused to the C-terminal region. The vaccine further comprises an aluminum oxide adjuvant that does not inhibit trans-sialidase enzymatic activity of the immunogen portion.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: February 26, 2019
    Inventor: Carlos de Baeremaecker Barros
  • Patent number: 9974846
    Abstract: The present invention relates to the field of the veterinary medicine of bovine animals. In particular the invention relates to a recombinant Trypanosoma theileri parasite, preferably comprising a heterologous nucleic acid sequence that is capable of encoding a protein for instance an antigen, a cytokine, a hormone, an antimicrobial protein, or an antibody. Also disclosed are uses of and methods for making and using the recombinant T. theileri parasite in medical or non-curative treatments; in particular as a sustained delivery vector for proteins to bovine animals, e.g. as a vaccine.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: May 22, 2018
    Assignee: THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH
    Inventor: Keith Roland Matthews
  • Patent number: 9861678
    Abstract: The present disclosure relates to a casein peptide for use in the treatment of an uterine infection in a female mammalian animal, to methods of treatment of such infections by administering to a female mammalian animal at least one casein peptide, to the use of casein peptide for the preparation of a pharmaceutical composition for treatment of uterine infection and to a kit for said treatment. The casein peptide is preferably a casein hydrolysate, e.g. obtained by trypsin hydrolysis of casein protein. The female mammalian animal is, in accordance with some embodiments, a lactating animal, the infection being a post-partum infection.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: January 9, 2018
    Assignee: Mileutis Ltd.
    Inventor: Jose Mario Iscovich
  • Patent number: 9669016
    Abstract: Embodiments are directed to compositions and methods for treating parasitic infections. Compounds have been identified from a library of anti-cancer drugs that serve as suitable agents for targeting trypanosomatids.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: June 6, 2017
    Assignees: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, UNIVERSITY OF SASKATCHEWAN
    Inventors: Rosa A. Maldonado, Miguel A. Vasquez, Jonathan R. Dimmock, Umashankar Das
  • Patent number: 9662384
    Abstract: The present invention relates to combination vaccines and methods for treating or preventing diseases or disorders in an animal caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PI3), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira hardj-prajitno, Leptospira icterohaemmorrhagiae, Leptospira hardjo-bovis and Leptospira pomona by administering to the animal an effective amount of a combination vaccine. The combination vaccine can be a whole or partial cell inactivated or modified live preparation.
    Type: Grant
    Filed: June 22, 2010
    Date of Patent: May 30, 2017
    Assignee: Zoetis Services LLC
    Inventors: Paul Joseph Dominowski, Michael John Huether, Mark D. Goodyear
  • Patent number: 9250239
    Abstract: Provided herein are vaccine compositions for control of Trypanosoma cruzi infection and Chagas disease. The compositions comprise plasmids encoding o GPI-anchored genes ASP-2, TcG-1, TcG2 and TcG4 from Trypanosoma cruzi; plasmids encoding cytokines IL12 and GM-CSF; and plasmids encoding a gene expression system. Certain vaccine compositions comprise recombinant proteins, selected from TcG-1, TcG2 and TcG4 from Trypanosoma cruzi. In another vaccination strategy, the recombinant proteins are replaced by lysates comprising Trypanosoma rangeli cells. Further provided herein are diagnosis compositions comprising 1) recombinant proteins, selected from TcG-1, TcG2 and TcG4 from Trypanosoma cruzi; 2) antibodies that specifically binds the TcG-1, TcG2 and TcG4 proteins; 3) sense and antisense polynucleotide sequences that encode the TcG-1, TcG2 and TcG4 proteins. Said compositions can be used in diagnosing and/or evaluating efficacy of treatments against Trypanosoma cruzi infection.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: February 2, 2016
    Assignee: The Board of Regents of the University of Texas System
    Inventor: Nisha J. Garg
  • Patent number: 9073984
    Abstract: The present disclosure is directed to reagents and methods of using the reagents to detect epitopes of Trypanosoma cruzi.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: July 7, 2015
    Assignee: ABBOTT LABORATORIES
    Inventors: Susan E. Brophy, David J. Hawksworth, Dinesh O. Shah, Robert W. Siegel, Bryan C. Tieman, Bailin Tu, Joan D. Tyner, Robert N. Ziemann
  • Patent number: 9028844
    Abstract: The present invention relates to a vaccine against Trypanosoma cruzi infection, useful in the prevention and/or treatment of the Chagas disease. More specifically, the present invention relates to a recombinant mutant trans-sialidase enzyme that can be used as an efficient vaccine, without side effects.
    Type: Grant
    Filed: March 14, 2007
    Date of Patent: May 12, 2015
    Assignees: VIB VZW, Universiteit Gent
    Inventors: Roland Contreras, Kristof De Vusser, Silvia Revelli
  • Patent number: 9017700
    Abstract: The present application describes a novel, advantageous purification method which guarantees the embryonation capability and the viability of a worm egg suspension. The T. suis worm eggs are first treated in a non-embryonated condition in a sulfuric acid solution at about =ph 2. Bacteria and viruses are thereby killed successfully. The germination number of yeasts and fungi is reduced. In a second step, the pH-value is increased and an orally tolerated preservative is added. Yeasts and fungi are thereby killed successfully. The suspension medium used in the second purification step can then be used as a culture medium for additional production (embryonation) and storage.
    Type: Grant
    Filed: March 31, 2008
    Date of Patent: April 28, 2015
    Assignee: Dr. Falk Pharma GmbH
    Inventors: Rudolf Wilhelm, Allan Kund Roepstorff, Christian Moliin Outzen Kapel
  • Patent number: 8992944
    Abstract: Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: March 31, 2015
    Assignee: Sanaria Inc.
    Inventors: B. Kim Lee Sim, Minglin Li, Richard E. Stafford, Stephen L. Hoffman
  • Patent number: 8986711
    Abstract: The present invention is generally related to the prevention of leishmaniasis in animals, particularly infection caused by Leishmania sp., based on the use of Leishmania infantum P36 protein or an immunogenic fragment of the latter, or involving an expression system for the mentioned protein or fragment—optionally in combination with a compound stimulating the production of a Th1-type cellular immune response—and comprising various vaccination protocols in application to Leishmania sp. based on the mentioned vaccine.
    Type: Grant
    Filed: February 21, 2002
    Date of Patent: March 24, 2015
    Assignees: Consejo Superior de Investigaciones Cientificas, Universidad de Zaragoza, Laboratorios Hipra, S.A.
    Inventors: Vicente Emilio Larraga Rodriguez De Vera, Gloria Gonzalez Aseguinolaza, Maria Jesus Ramiro Ibanez, Juan Antonio Castillo Hernandez, Javier Lucientes Curdi
  • Patent number: 8968749
    Abstract: The present invention refers to the recombinant vaccine against canine visceral leishmaniasis containing the recombinant A2 protein and saponin, monophosphoryl lipid A, or aluminum hydroxide plus CpG as an adjuvant, allowing the distinction between vaccinated and infected animals through conventional ELISA or immunofluorescence tests that employ antigens of promastigote forms of Leishmania.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: March 3, 2015
    Assignee: Universidade Federal de Minas Gerais—UFMG
    Inventors: Ana Paula Salles Moura Fernandes, Christiane De Freitas Abrantes, Eduardo Antonio Ferraz Coelho, Ricardo Tostes Gazzinelli
  • Patent number: 8968750
    Abstract: The present invention relates to peptides comprising at least one antigenic determinant or epitope of an apicomplexan Ferlin, Ferlin-like protein and/or another C2-domain containing protein for use as malaria vaccines. It further relates to compositions comprising said peptides and to the use of such compositions as malaria vaccines.
    Type: Grant
    Filed: December 6, 2010
    Date of Patent: March 3, 2015
    Assignee: Ruprecht-Karls-Universität Heidelberg
    Inventors: Ann-Kristin Mueller, Eva Morath
  • Patent number: 8916168
    Abstract: Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise Leishmania sterol 24-c-methyltransferase (SMT) polypeptides, portions, variants and/or fusions, as well as polynucleotides encoding SMT polypeptides, portions, variants and/or fusions.
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: December 23, 2014
    Assignee: Infectious Disease Research Institute
    Inventors: Steven Reed, Yasuyuki Goto
  • Publication number: 20140370099
    Abstract: Compositions and methods comprising asymmetrical artificial antigen presenting cells (aAPCs) are disclosed. The non-spherical aAPCs more closely mimic endogenous cell-cell interactions and can be used for antigen-specific immunotherapy.
    Type: Application
    Filed: December 10, 2012
    Publication date: December 18, 2014
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Jordan J. Green, Joel C. Sunshine, Karlo Perica, Jonathan Schneck
  • Patent number: 8911746
    Abstract: Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise fusion polypeptides comprising multiple Leishmania antigens, in particular, KMP11, SMT, A2 and/or CBP, or immunogenic portions or variants thereof, as well as polynucleotides encoding such fusion polypeptides.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: December 16, 2014
    Assignee: Infectious Disease Research Institute
    Inventors: Yasuyuki Goto, Steven G. Reed
  • Patent number: 8900598
    Abstract: A vaccine against the Chagas disease, capable of stimulating the immune response against the trans-sialidase virulence factor of the Trypanosoma cruzi parasite, which is a multicomponent vaccine comprising: (a) an immunogenic portion formed by one or more recombinant or synthetic polypeptides or fractions of thereof and (b) one or more polynucleotides including the regions codifying one or more immunogenic polypeptides, or a monocomponent vaccine comprising at least one component selected among an immunogenic portion formed by one or more recombinant or synthetic polypeptides or fractions of them and a group of polynucleotides including the regions codifying one or more immunogenic polypeptides derived from Trypanosoma cruzi and pharmaceutical compositions containing said multicomponent and monocomponent vaccines, the procedures for obtaining the immunogen portion of said vaccines and the nucleic acid used in the procedure.
    Type: Grant
    Filed: October 30, 2008
    Date of Patent: December 2, 2014
    Inventor: Carlos de Baeremaecker Barros
  • Patent number: 8900825
    Abstract: The invention provides novel immunogenic proteins LigA and LigB from Leptospira for use in the development of effective vaccines and antibodies, as well as improved diagnostic methods and kits.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: December 2, 2014
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Yung-Fu Chang, Raghavan U. M. Palaniappan
  • Patent number: 8877213
    Abstract: Targeted disruption of the centrin gene leads to attenuation of growth in the Leishmania. Preferred embodiments of the invention provide attenuated strains of Leishmania useful for the preparation of immunogenic preparations including vaccines against a disease caused by infection with a virulent Leishmania strain and as tools for the generation of immunological and diagnostic reagents. Other preferred embodiments provide related immunogenic compositions, methods of generating an immune response, methods for producing a vaccine, and methods of forming attenuated strains of Leishmania.
    Type: Grant
    Filed: November 15, 2010
    Date of Patent: November 4, 2014
    Assignees: The United States of America as Represented by the Secretary of the Department of Health and Human Services, Indian Council of Medical Research
    Inventors: Hira L. Nakhasi, Angamuthu Selvapandiyan, Alain Debrabant, Robert C. Duncan, Poonam Salotra, Gannavaram Sreenivas
  • Patent number: 8871225
    Abstract: The present invention provides vectors that contain and express in vivo Leishmania KMP11 or an epitope thereof that elicits an immune response in a dog against Leishmania, compositions comprising said vectors, methods of vaccination against Leishmania, and kits for use with such methods and compositions.
    Type: Grant
    Filed: July 20, 2010
    Date of Patent: October 28, 2014
    Assignee: Merial Limited
    Inventor: Laurent Bernard Fischer
  • Publication number: 20140255448
    Abstract: The present invention refers to the recombinant vaccine against canine visceral leishmaniasis containing the recombinant A2 protein and saponin, monophosphoryl lipid A, or aluminum hydroxide plus CpG as an adjuvant, allowing the distinction between vaccinated and infected animals through conventional ELISA or immunofluorescence tests that employ antigens of promastigote forms of Leishmania.
    Type: Application
    Filed: May 27, 2014
    Publication date: September 11, 2014
    Inventors: Ana Paula Salles Moura FERNANDES, Christiane De Freitas Abrantes, Eduardo Antonio Ferraz Coelho, Ricardo Tostes Gazzinelli
  • Patent number: 8821896
    Abstract: Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: September 2, 2014
    Assignee: Sanaria Inc.
    Inventors: B. Kim Lee Sim, Minglin Li, Richard E. Stafford, Stephen L. Hoffman
  • Patent number: 8778348
    Abstract: The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by Trypanosoma protozoa. Provided are recombinant protein antigens, compositions, and methods for the production and use of such antigens and vaccine compositions.
    Type: Grant
    Filed: April 28, 2008
    Date of Patent: July 15, 2014
    Assignee: iBio Inc.
    Inventors: Elisabeth Knapp, Vidadi Yusibov
  • Publication number: 20140193459
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Application
    Filed: May 3, 2013
    Publication date: July 10, 2014
    Applicant: Infectious Disease Research Institute
    Inventors: Steven G. Reed, Darrick Carter
  • Patent number: 8771710
    Abstract: The present invention relates generally to a fusion protein made from a synthetic gene construct comprising of elements derived from the Leishmania antigens K26, K39, and K9. The fusion protein is particularly useful in the diagnosis of leishmaniasis, particularly visceral leishmaniasis in animals such as humans and dogs.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: July 8, 2014
    Assignee: Infectious Disease Research Institute
    Inventors: Ajay Bhatia, Steven G. Reed
  • Patent number: 8765145
    Abstract: The present invention pertains to the protection against malaria. More particularly, the invention is based on the characterization of a novel liver and sporozoite-stage P. falciparum antigen, referred to as LSA-5. This antigen is highly antigenic and the prevalence of antibodies in subjects living in endemic areas is extremely high (ca. 90%). The invention concerns antigenic peptides, mixtures thereof, or polypeptides, mixotopes and conjugates comprising part of the sequence of LSA-5, as well as immunogenic compositions, vaccines and kits comprising these.
    Type: Grant
    Filed: June 13, 2006
    Date of Patent: July 1, 2014
    Assignee: Vac-4-All Pte. Ltd.
    Inventors: Pierre Druilhe, Karima Brahimi-Zeghidour
  • Publication number: 20140178437
    Abstract: The invention relates to the use of a food additive comprising at least one phytonutrient in order to stimulate vaccine immunity against apicomplexa in non-human monogastric animals, such as poultry or pigs, or in ruminants, such as a cattle, sheep or goats.
    Type: Application
    Filed: January 31, 2012
    Publication date: June 26, 2014
    Applicant: PANCOSMA S.A.
    Inventors: David Bravo, Hyun Lillehoj
  • Publication number: 20140161837
    Abstract: The disclosure provides a vaccine adjuvant, including a polysaccharide derived from Antrodia camphorata (also named Antrodia cinnamomea or Taiwanofungus camphoratus) fruiting body, wherein the molecular weight of the polysaccharide is greater than 100 K Da. Furthermore, the polysaccharide is obtained by an extraction process, and the extraction process includes: (a) adding powder of the Antrodia camphorata fruiting body into water to form a mixture; (b) heating the mixture under reflux; (c) after step (b), removing an insoluble matter from the mixture; (d) after step (c), adding ethanol into the mixture to perform a precipitating step and obtain a precipitate; and (e) performing an isolating step to the precipitate to obtain a fraction the molecular weight of which is greater than 100 K Da of the precipitate.
    Type: Application
    Filed: December 9, 2013
    Publication date: June 12, 2014
    Applicant: Industrial Technology Research Institute
    Inventors: I-Horng PAN, I-Haung LU, Hsin-Jan YAO, Hsin-Chieh WU, Chi-Chien LIN
  • Patent number: 8734807
    Abstract: Schistosomiasis mansoni is caused by flukes called Schistosoma(es) that enters the human body through the skin in Schistosoma infested waters. The Schistosomes travel from the skin into human blood vessels where they mate, produce antigen containing eggs that travel from the blood vessels into the small intestines, where they are released in the human feces. Male and female Schistosome mates in human blood vessels, male Schistosomes secrete a protein called TGR ? protein to the Trk receptor sites on the females Schistosomes membranes. The process stimulates the formation of chemical SmInAct in female Schistosomes, a chemical necessary for the female Schistosomes to produce eggs. This novel technique describes new methods to inhibit Trk receptor sites on female Schistosome membranes using Trk inhibitor agent to prevent TGR ? proteins from binding to the Trk receptor sites. Thus, preventing SmInAct from being created in female Schistosomes, preventing production of eggs and Schistosomiasis.
    Type: Grant
    Filed: April 6, 2013
    Date of Patent: May 27, 2014
    Inventor: Gabriel Langlois-Rahme
  • Patent number: 8734815
    Abstract: The present invention refers to the recombinant vaccine against canine visceral leishmaniasis containing the recombinant A2 protein and saponin, as an adjuvant, allowing the distinction between vaccinated and infected animals through conventional ELISA or immunofluorescence tests that employ antigens of promastigote forms of Lesihmania.
    Type: Grant
    Filed: July 20, 2007
    Date of Patent: May 27, 2014
    Assignee: Universidade Federal de Minas Gerais
    Inventors: Ana Paula Salles Moura Fernandes, Christiane De Freitas Abrantes, Eduardo Antonio Ferraz Coelho, Ricardo Tostes Gazzinelli
  • Publication number: 20140127266
    Abstract: Disclosed herein are methods of making a vaccine against Entamoeba histolytica and methods of immunizing a subject using such vaccine.
    Type: Application
    Filed: December 17, 2012
    Publication date: May 8, 2014
    Applicant: University of Central Florida Research Foundation, Inc.
    Inventor: Henry Daniell
  • Patent number: 8715697
    Abstract: The invention relates to the field of combating leishmaniases. Said invention results from the isolation, from wild isolates of Leishmania major, of a protein-coding gene known as LmPDI which has two regions that are identical to the sequence (Cys-Gly-His-Cys) of the potential active site of the protein disulphide isomerase (PDI). The LmPDI protein is predominantly expressed in the most virulent isolates of the parasite. Said protein forms a novel therapeutic target for developing anti-leishmaniasis medicaments and a novel element that can be used in the composition of immunogenic, and possibly vaccinating, preparations which are intended to protect a human or animal host against Leishmania.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: May 6, 2014
    Assignees: Institut Pasteur de Tunis, Institut Pasteur
    Inventors: Yosser Ben Achour, Mehdi Chenik, Hechmi Louzir, Koussay Dellagi
  • Patent number: 8709445
    Abstract: This invention provides compositions for inducing an immune response in a vertebrate host against a protozoan parasite. In certain embodiments the composition comprises a protozoan parasite comprising a psoralen-modified DNA, whereby said protozoan parasite is killed but metabolically active (KBMA); and optionally a Toll-like receptor agonist.
    Type: Grant
    Filed: July 31, 2008
    Date of Patent: April 29, 2014
    Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventors: Noah A. Craft, Kevin W. Bruhn, Ron A. Birnbaum
  • Patent number: 8703147
    Abstract: The present invention provides compositions and methods useful in the treatment or prevention of a condition caused by or associated with infection by Plasmodium falciparum, such as malaria. The compositions include various antigens of Plasmodium falciparum, both alone and in combination. The invention further includes fragments of the antigens.
    Type: Grant
    Filed: November 5, 2008
    Date of Patent: April 22, 2014
    Assignee: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Alan Cowman, James Beeson, Alexander Gerd Maier, Kristina E. M. Persson, Jonathan S. Richards, Sash Lopaticki
  • Patent number: 8673311
    Abstract: The present invention relates to a method of coating a spore with one or more therapeutic agents. The present invention also relates to a coated spore obtained by the method of the present invention and the use of the coated spore as a vaccine.
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: March 18, 2014
    Assignee: Royal Holloway and Bedford New College
    Inventors: Simon Michael Cutting, Hong Anh Huynh
  • Publication number: 20140056940
    Abstract: This invention relates to adjuvant formulations comprising various combinations of triterpenoids, sterols, immunomodulators, polymers, and Th2 stimulators; methods for making the adjuvant compositions; and the use of the adjuvant formulations in immunogenic and vaccine compositions with different antigens. This invention further relates to the use of the formulations in the treatment of animals.
    Type: Application
    Filed: August 29, 2013
    Publication date: February 27, 2014
    Inventors: Paul Joseph Dominowski, Ramasamy Mannar Mannan, Richard Lee Krebs, James Richard Thompson, Tedd Alan Childers, Mary Kathryn Olsen, Robert John Yancey, JR., Risini Dhammika Weeratna, Shucheng Zhang, Cedo Martin Bagi
  • Publication number: 20140037716
    Abstract: The present invention relates to immunogenic compositions for modulating the immune system, comprising a therapeutically effective quantity of two or more immuno-active antigenic agents with pathogen-associated molecular patterns (PAMPs) and/or danger-associated molecular patterns (DAMPs) and one or more physiologically acceptable carriers, excipients, diluents or solvents. The immunogenic compositions according to the present invention are used for producing medicaments for preventing and/or treating, and for preventing and/or treating infectious diseases, auto-immune diseases, allergic diseases, inflammation, arthritis, inflammatory diseases, transplant rejection, affections caused by vascular disorders, diseases caused by haemorrhagic or ischaemic cardiovascular accidents, ischaemia, heart attack and haemorrhagia leading to tissue destruction, heart, kidney, respiratory or liver insufficiency, cancer, malign and benign tumours and neoplasia.
    Type: Application
    Filed: March 19, 2012
    Publication date: February 6, 2014
    Inventor: Alexandre Eduardo Nowill
  • Publication number: 20140030293
    Abstract: The invention relates to a new adjuvant and to its use in combination with an antigen.
    Type: Application
    Filed: November 10, 2011
    Publication date: January 30, 2014
    Applicant: LABORATORIOS LETI, S.L.
    Inventors: Carlos Alonso - Bedate, Manuel Soto - Alvarez, Nuria Parody - De La Fuente, Yago Pico De Coana - Suarez
  • Patent number: 8617575
    Abstract: Immunity against protozoan is conferred on an animal by a method comprising orally administering to an animal a transformed plant cell comprising a polynucleotide encoding a protective antigen against protozoiasis development, a transformed plant or its progeny or clone comprising the transformed cell, a propagation material of the plant or its progeny or clone, a processed material or extract of the above cell, plant, or its progeny or clone, or propagation material, or a protective antigen against protozoiasis development isolated from the transformed plant cell or the transformed plant or its progeny or clone.
    Type: Grant
    Filed: May 30, 2005
    Date of Patent: December 31, 2013
    Assignees: Kitasato Daiichi Sankyo Vaccine Co., Ltd., National Institute of Advanced Industrial Science and Technology
    Inventors: Akira Ito, Toru Gotanda, Shigeki Kobayashi, Katsumi Kume, Takeshi Matsumura
  • Publication number: 20130337014
    Abstract: Disclosed herein are compositions for the treatment of a disease in an animal including yeast extract of Saccharomyces cerevisiae, Bacillus licheniformis or Bacillus subtilis spores, and a carrier. Also included are animal feed compositions including the composition for the prevention, control and/or treatment of a disease in an animal and an animal's food/feed. The compositions are useful to prevent, control, and treat diseases such as necrotic enteritis in poultry when used in combination with an anticoccidal ionophore or coccidiosis vaccine.
    Type: Application
    Filed: August 22, 2013
    Publication date: December 19, 2013
    Applicant: Zoetis Products LLC
    Inventors: James Skinner, Doug Rupp
  • Patent number: 8574598
    Abstract: The invention relates to nucleic acid constructions, characterized in that they comprise nucleic acids which are isolated in the sense position and which are capable of coding for an immunogenic protein of promastigotes or amastigotes of Leishmania, said nucleic acids responding to one of the sequences SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5 et SEQ ID No. 11 and coding for a protein respectively exhibiting a sequence SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10 et SEQ ID No. 12. The invention can be used for over-expression of the genes of Leishmania coding for an excretion/secretion antigen.
    Type: Grant
    Filed: November 19, 2004
    Date of Patent: November 5, 2013
    Assignee: Institut de Recherche Pour le Developpement (IRD)
    Inventors: Jean-Loup Lemesre, Mireille Cavaleyra, Denis Sereno, Philippe Holzmuller
  • Publication number: 20130273001
    Abstract: The present invention relates to an immunostimulating agent comprising at least one chemically modified RNA. The invention furthermore relates to a vaccine which comprises at least one antigen in combination with the immunostimulating agent. The immunostimulating agent according to the invention and the vaccine according to the invention are employed in particular against infectious disease or cancer diseases.
    Type: Application
    Filed: March 25, 2013
    Publication date: October 17, 2013
    Inventors: Ingmar HOERR, Florlan Von Der Mulbe, Steve Pascolo
  • Patent number: 8551500
    Abstract: The invention concerns an immunogenic composition comprising: i) an antigenic polypeptide consisting of a fragment of the protein histone H2B of Leishmania, said fragment including the N-terminal region of said protein histone H2B, and ii) an adjuvant stimulating the immune response.
    Type: Grant
    Filed: May 8, 2008
    Date of Patent: October 8, 2013
    Assignees: Institut Pastuer, Institut Pasteur De Tunis
    Inventors: Mehdi Chenik, Hechmi Louzir, Koussay Dellagi
  • Publication number: 20130224249
    Abstract: Recombinant, attenuated parasites are transformed or transfected with nucleic acid molecules which provoke an immunostimulatory and protective response in subjects. Preferably, the parasite is Trypanosoma cruzi, especially strain CL-14, and the transforming nucleic acid molecule encodes for a cancer testis antigen, such as NY-ESO-1.
    Type: Application
    Filed: September 1, 2011
    Publication date: August 29, 2013
    Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.
    Inventors: Bruno Galvao Filho, Ricardo Tostes Gazzinelli, Caroline Junqueira Giusta, Santuza Maria Ribeiro Teixeira
  • Publication number: 20130216578
    Abstract: The present invention relates to the field of the veterinary medicine of bovine animals. In particular the invention relates to a recombinant Trypanosoma theileri parasite, preferably comprising a heterologous nucleic acid sequence that is capable of encoding a protein for instance an antigen, a cytokine, a hormone, an antimicrobial protein, or an antibody. Also disclosed are uses of and methods for making and using the recombinant T. theileri parasite in medical or non-curative treatments; in particular as a sustained delivery vector for proteins to bovine animals, e.g. as a vaccine.
    Type: Application
    Filed: July 29, 2011
    Publication date: August 22, 2013
    Inventor: Keith Roland Matthews
  • Patent number: 8475767
    Abstract: The present invention provides methods of killing, inhibiting the growth, and/or inhibiting the reproduction of kinetoplastid protozoan with hydrophobic signal sequence peptides and compositions including such hydrophobic signal sequence peptides.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: July 2, 2013
    Assignee: University of George Research Foundation, Inc.
    Inventors: John M. Harrington, Stephen L. Hajduk
  • Patent number: 8425919
    Abstract: Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise fusion polypeptides comprising multiple Leishmania antigens, in particular, KMP11, SMT, A2 and/or CBP, or immunogenic portions or variants thereof, as well as polynucleotides encoding such fusion polypeptides.
    Type: Grant
    Filed: May 15, 2009
    Date of Patent: April 23, 2013
    Assignee: Infectious Disease Research Institute
    Inventors: Yasuyuki Goto, Steven G. Reed
  • Patent number: 8410258
    Abstract: Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise fusion polypeptides comprising multiple Leishmania antigens, in particular, KMP11, SMT, A2 and/or CBP, or immunogenic portions or variants thereof, as well as polynucleotides encoding such fusion polypeptides.
    Type: Grant
    Filed: November 18, 2009
    Date of Patent: April 2, 2013
    Assignee: Infections Disease Research Institute
    Inventors: Yasuyuki Goto, Steven G. Reed
  • Publication number: 20130071430
    Abstract: It is intended to provide a vaccinia virus that specifically proliferates in a cancer cell and destroys the cancer cell and to provide use of the virus in cancer treatment. The present invention provides a microRNA-controlled vaccinia virus, in which a target sequence of a microRNA less expressed in a cancer cell than in a normal cell is inserted in a 3? untranslated region of B5R gene associated with viral proliferation in a vaccinia virus, wherein the microRNA-controlled vaccinia virus specifically proliferates in the cancer cell and has an oncolytic property that destroys the cancer cell.
    Type: Application
    Filed: March 15, 2011
    Publication date: March 21, 2013
    Applicant: THE UNIVERSITY OF TOKYO
    Inventors: Takafumi Nakamura, Mina Hikichi, Hideaki Tahara, Hisatoshi Shida, Minoru Kidokoro